Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study

Ponikowski, 2016, Eur Heart J, 37, 2129, 10.1093/eurheartj/ehw128 Yancy, 2017, Circulation, 136, e137, 10.1161/CIR.0000000000000509 Philbin, 1996, Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals, Am J Cardiol, 77, 832, 10.1016/S0002-9149(97)89177-1 Cleland, 2002, Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey, Lancet, 360, 1631, 10.1016/S0140-6736(02)11601-1 Fonarow, 2008, Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure), Am J Cardiol, 102, 1524, 10.1016/j.amjcard.2008.07.045 Ouwerkerk, 2017, Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study, Eur Heart J, 38, 1883, 10.1093/eurheartj/ehx026 Voors, 2016, A systems biology study to tailored treatment in chronic heart failure: rationale, design, and baseline characteristics of BIOSTAT-CHF, Eur J Heart Fail, 18, 716, 10.1002/ejhf.531 Liao, 2007, Safety and efficacy of statins in Asians, Am J Cardiol, 99, 410, 10.1016/j.amjcard.2006.08.051 Woo, 1995, High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese, Br J Clin Pharmacol, 40, 141 Yasuda, 2008, The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies, Clin Pharmacol Ther, 84, 417, 10.1038/clpt.2008.141 Zhou, 1989, Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites, N Engl J Med, 320, 565, 10.1056/NEJM198903023200905 Okamoto, 2013, Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study, Int J Cardiol, 164, 238, 10.1016/j.ijcard.2012.11.051 Kishida, 1990, Evaluation of a new vasodilating beta-blocking agent, carvedilol, in exertional angina using holter monitoring, Jpn Heart J, 31, 449, 10.1536/ihj.31.449 Ogihara, 1991, Clinical efficacy of carvedilol in severe hypertension, J Cardiovasc Pharmacol, 18, S69, 10.1097/00005344-199118041-00014 Lam, 2016, Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry, Eur Heart J, 37, 3141, 10.1093/eurheartj/ehw331 Lam, 2013, Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry, Eur J Heart Fail, 15, 928, 10.1093/eurjhf/hft045 Friedman, 2010, Regularization paths for generalized linear models via coordinate descent, J Stat Softw, 33, 1, 10.18637/jss.v033.i01 Hastie, 2009 Buuren, 2011, Multivariate imputation by chained equations in R, J Stat Software, 45, 1, 10.18637/jss.v045.i03 Peduzzi, 1995, Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates, J Clin Epidemiol, 48, 1503, 10.1016/0895-4356(95)00048-8 Peduzzi, 1996, A simulation study of the number of events per variable in logistic regression analysis, J Clin Epidemiol, 49, 1373, 10.1016/S0895-4356(96)00236-3 Horton, 2007, Much ado about nothing: a comparison of missing data methods and software to fit incomplete data regression models, Am Stat, 61, 79, 10.1198/000313007X172556 Ng, 2014, Incidence of discontinuation of angiotensin-converting enzyme inhibitors due to cough, in a primary healthcare centre in Singapore, Singapore Med J, 55, 146, 10.11622/smedj.2014034 Lee, 2001, Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor –58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus, Metabolism, 50, 1346, 10.1053/meta.2001.27212 Dans, 2010, In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events, PLoS One, 5, e13694, 10.1371/journal.pone.0013694 Yusuf, 2011, Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey, Lancet, 378, 1231, 10.1016/S0140-6736(11)61215-4 Dokainish, 2017, Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study, Lancet Glob Health, 5, e655, 10.1016/S2214-109X(17)30196-1 Guan, 2015, National quality assessment evaluating spironolactone use during hospitalization for acute myocardial infarction (AMI) in China: China patient-centered evaluation assessment of cardiac events (PEACE)-retrospective AMI study, 2001, 2006, and 2011, J Am Heart Assoc, 4, e001718, 10.1161/JAHA.114.001718 Konstam, 2009, Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial, Lancet, 374, 1840, 10.1016/S0140-6736(09)61913-9 Packer, 1999, Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group, Circulation, 100, 2312, 10.1161/01.CIR.100.23.2312 Hori, 2004, Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the multicenter carvedilol heart failure dose assessment (MUCHA) trial, Am Heart J, 147, 324, 10.1016/j.ahj.2003.07.023 Sugioka, 2005, Early recovery of impaired coronary flow reserve by carvedilol therapy in patients with idiopathic dilated cardiomyopathy: a serial transthoracic Doppler echocardiographic study, J Am Coll Cardiol, 45, 318, 10.1016/j.jacc.2004.10.019 Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001